查詢結果分析
來源資料
頁籤選單縮合
題名 | Pulmonary Squamous Cell Carcinoma Harboring EGFR Exon 19 Mutation Responded Dramatically to EGFR-TKI--A Case Report=具表皮細胞生長因子接受器突變之肺麟狀細胞癌病患使用上皮細胞生長因子接收器-酪胺酸酶抑制劑呈顯著治療效果:病例報告 |
---|---|
作者姓名(中文) | 李凱靈; 林賜恩; 鍾政錦; 蕭世欣; 鍾啟禮; | 書刊名 | 胸腔醫學 |
卷期 | 30:3 2015.06[民104.06] |
頁次 | 頁157-163 |
分類號 | 415.468 |
關鍵詞 | 表皮細胞生長因子接受器突變; 上皮細胞生長因素接收器-酪胺酸酶抑制劑; 肺麟狀細胞癌; Epidermal growth factor receptor mutation,; EGFR; EGFR tyrosine kinase inhibitor; TKI; Pulmonary squamous cell carcinoma; |
語文 | 英文(English) |
中文摘要 | 表皮細胞生長因子接受器(Epidermal growth factor receptor,簡稱EGFR)的基因突變常見於非小細胞肺癌病患,尤其是從不抽菸、女性和肺腺癌患者。擁有此突變之病患有較好的EGFR 酪胺酸.抑制劑(Tyrosine kinase inhibitor,簡稱TKI)治療效果和預後。我們提出的個案為一個不抽菸女性患有肺麟狀細胞癌併發腦部遠處轉移,卻罕見地擁有EGFR exon 19 突變,並對EGFR TKI 治療有顯著的療效。此篇病例報告指出EGFR 基因突變分析應可實行於肺麟狀細胞癌的病患,尤其是具有亞裔、女性和從不抽菸的特徵者,而且可為此類病人提供使用標靶治療的機會。 |
英文摘要 | Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。